Biohaven Ltd

BHVN exhibited an active support failure through the prior consolidation zone on elevated volume, confirming seller control and signaling medium-term distribution. Short-term momentum is negative with price trading below declining EMAs, reinforcing immediate downside participation. While RSI approaches oversold levels, structural breakdown outweighs mean-reversion potential. Sell now into the former support zone as it transitions to resistance.

• ↑Q4 net sales hit $190 M (+440% YoY) with 1.6 M+ prescriptions
• ↑Pfizer collaboration injects $500 M, boosting cash and overseas launch
• ↓Q4 adjusted net loss of $125 M and negative earnings yield